1041 / 1851
For patients with
NSCLC
and molecular
mutations or
rearrangements
targeted with systemic therapy,
metastatic
progression
frequently
occurs in
limited
number and location
subgroup
of patients who can enjoy significantly longer
treatment responses and prolonged survival
Oligometastatic NSCLC